The biological drug API manufacturing market is estimated to grow at a CAGR of 9.5% in the first half of the forecast period. In 2018, Mammalian cell culture systems submarket represents the largest submarket within the biological drug API manufacturing industry.

How this 211-page report delivers:
  • Biological Drug API Manufacturing Services market forecast to 2029
  • Biological Drug API Manufacturing Services market forecast to 2029 by Expression Systems:
  • Mammalian cell culture
  • Microbial fermentation
  • Other expression platforms

Biological Drug API Manufacturing Services market forecast to 2029 by Therapeutic Area:
  • Monoclonal antibody (mAb) therapies
  • Vaccines
  • Insulin therapies
  • Interferon therapies
  • Growth hormones
  • Other Therapeutic Areas

Biological Drug API Manufacturing Services market forecast to 2029 by Regional and National Market:
  • North America: US, Canada
  • Europe: Germany, France, the UK, Switzerland, Spain, Italy, Rest of Europe
  • BRIC: Brazil, Russia, China, India
  • Japan
  • South Korea
  • Singapore
  • RoW

Profiles leading companies that offer biotech API manufacturing services to the pharmaceutical industry. Leading CMOs profiled in this report are:
  • Abbvie
  • Boehringer Ingelheim BioXcellence
  • Catalent
  • Celltrion
  • Cytovance Biologics
  • Fujifilm Diosynth Biotechnologies
  • GSK
  • Lonza
  • Patheon N.V.
  • Rentschler Biopharma
  • Samsung BioLogics
  • Sandoz
  • Teva

Provides qualitative analysis: SWOT and STEP Analysis of the biological drug API manufacturing market.

Key questions answered by this report:
  • How is the biological drug API manufacturing services market evolving?
  • What is driving and restraining the biological drug API manufacturing services market?
  • What are the market shares of each main segment of the overall biological drug API manufacturing services market in 2018?
  • How will each main biological drug API manufacturing services submarket grow over the forecast period and how much revenue will these submarkets account for in 2029?
  • How will the market shares for biological drug API manufacturing services submarkets develop from 2019 to 2029?
  • What will be the main drivers for the overall market from 2019 to 2029?
  • How will political and regulatory forces influence the regional markets and submarkets?
  • Will leading national biological drug API manufacturing services markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2029 and which countries will lead the market in 2029?
  • Who are the leading companies and what are their prospects?
  • What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
  • How will the industry evolve during the period 2019 to 2029, and which trends will be important